Hilario N.
- Country
- France
- Department
- Department of pulmonology
Research Overview
- HydroxyChloroquine as steroid-sparing Agent in Extra-pulmonary SARcoidosis. A multicenter, prospective, placebo-controlled, randomized trial. CAESAR
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Idiopathic Pulmonary Fibrosis
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Admilparant in Participants with Progressive Pulmonary Fibrosis
Data & Insights
Has run more than one trial at 236 of 352 partner sites.
Specializations
Pulmonary Fibrosis Research
This investigator specializes in various forms of pulmonary fibrosis, with particular emphasis on idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Their research encompasses innovative therapeutic approaches for managing these conditions.
- Disease progression monitoring
- Lung function assessment
- Novel therapeutic interventions
Sarcoidosis Studies
The investigator conducts research in both pulmonary sarcoidosis and extra-pulmonary sarcoidosis, focusing on inflammation control and treatment optimization. Their work includes evaluation of various therapeutic agents for managing sarcoidosis manifestations.
- Granulomatous inflammation
- Treatment response assessment
- Steroid-sparing approaches
Interstitial Lung Disease
Their expertise extends to various forms of interstitial lung disease (ILD), including systemic sclerosis-associated ILD. The research focuses on evaluating treatment efficacy and investigating combination therapies.
- Progressive ILD management
- Inflammatory component assessment
- Long-term treatment outcomes
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.